Summary Slide.png (120.56 kB)

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States

Version 2 2021-07-14, 12:41

Version 1 2021-05-24, 17:57

media

posted on 2021-07-14, 12:41 authored by Linda Harris, Gilbert L’Italien, Tom O’Connell, Zacharia Hasan, Susan Hutchinson, Sylvia Lucas

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

Usage metrics

Keywords

Migraine CGRP 5-HT1F Rimegepant Ubrogepant Lasmiditan Triptan Eligibility Budget impact Model

Licence

CC BY-NC 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM